Sotorasib is a selective irreversible inhibitor of the G12C-activated KRAS oncogene, present in approximately 13% of non–small-cell lung cancers. In a single-group, phase 2 trial involving 126 patients with previously treated KRAS –mutated NSCLC, 37% had a response.
https://www.nejm.org/doi/full/10.1056/NEJMoa2103695